The Cholecystokinin Receptor Antagonist L-364,718 Reduces Taurocholate-Induced Pancreatitis in Rats

International Journal of Pancreatology

Volumn 20, Issue 3, 1996, Pages 205-211

  Kim, Kyung Hwan ^a   Lee, Min Goo ^a   Kim, Dong Goo ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Acute pancreatitis; Camostat; Cholecystokinin; L 364,718

Indexed keywords

CAMOSTAT; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; DEVAZEPIDE; TAUROCHOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROTECTION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; EDEMA; INFLAMMATORY INFILTRATE; MALE; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL; RAT;

AMYLASES; ANIMALS; BENZODIAZEPINONES; CHOLAGOGUES AND CHOLERETICS; DEVAZEPIDE; GABEXATE; GUANIDINES; HISTOCYTOCHEMISTRY; HORMONE ANTAGONISTS; MALE; PANCREAS; PANCREATITIS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CHOLECYSTOKININ; SINCALIDE; TAUROCHOLIC ACID; TRYPSIN INHIBITORS;

EID: 0030445881     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02803770     Document Type: Article

References (35)

1. Cornfield AP, Cooper MI, Williamson RCN. Acute pancreatitis: a lethal disease of increasing incidence. Gut 1985; 26: 724-728.
2. Klar E. Etiology and pathology of acute pancreatitis. Helvetica Chirurgica Acta 1992; 59: 7-16.
3. Muramatsu M, Fujii S. Inhibitory effects of ω-guanidoesters on trypsin, plasmin, plasma kallikrein and thrombin. Biochim Biophys Acta 1972; 268: 221-224.
4. 1 esterase. Biochim Biophys Acta 1977; 484: 417-422.
5. Grendell JH. Experimental pancreatitis. Curr Opinion Gastroenterol 1992; 8: 808-813.
6. Markus ML, Adler G. Acute pancreatitis. Curr Opinion Gastroenterol 1992; 8: 817-823.
7. Case RM. Cellular mechanisms of control and secretion in the exocrine pancreas. Curr Opinion Gastroenterol 1990; 6: 731-738.
8. Chang RS, Lotti VJ, Monaghan RL, Birnbaum J, Stapley EO, Goetz MA, Albers-Schonberg G, Patchett A, Liesch JM, Hensens OD. A potent nonpeptide cholecystokinin antagonist selective for peripheral tissue isolated from Aspergillus alliaceus. Science 1985; 230: 177-179.
9. Lotti VJ, Pendleton RG, Gould RJ, Hanson HM, Chang RSL, Clineschmidt BV. In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist. J Pharmacol Exp Ther 1987; 241: 103-109.
10. Bruzzone R. The molecular basis of enzyme secretion. Gastroenterotogy 1990; 99: 1157-1176.
11. Yu DH, Huang SC, Wank SA, Mantney S, Gardner JD, Jensen RT. Pancreatic receptors for cholecystokinin: evidence for three receptor classes. Am J Physiol 1990; 258: G86-95.
12. Sjövall S, Ahrén B, Stenram U. Effects of the specific cholecystokinin antagonist L 364,718 in experimental acute pancreatitis in the rat. Eur Surg Res 1988; 20: 325-329.
13. Tarpila E, Larson L, Lilja I, Ihse I. Proglumide treatment in bile-induced acute experimental pancreatitis. Int J Pancreatol 1988; 3: 195-202.
14. Leonhardt U, Seidensticker F, Fussek M, Stockmann F, Creutzfeldt W. Influence of the CCK-antagonist loxiglumide on bile-induced experimental pancreatitis. Int J Pancreatol 1991; 10: 73-80.
15. Ko TC, Bertram MF, Prinz RA, Castelli M, Djuricin G, Jacobs HK. Effect of somatostatin analogue and cholecystokinin antagonist on bile-induced acute canine pancreatitis. Am Surg 1992; 58: 213-219.
16. Makovec F, Bani M, Cereda R, Chiste R, Revel L, Rovati LC, Setnikar I, Rovati LA. Protective effects of CR 1409 (cholecystokinin antagonist) on experimental pancreatitis in rats and mice. Peptides 1986; 7: 1159-1164.
17. Setnikar I, Bani M, Cereda R, et al. Loxiglumide protects against experimental pancreatitis. Arzneimittelforschung 1987; 37: 1172-1174.
18. Wisner JR, Renner IG. Asperlicin, a nonpeptidal cholecystokinin receptor antagonist, attenuates sodium taurocholate-induced acute pancreatitis in rats. Pancreas 1988; 3: 174-179.
19. Kosidlo S, Rydzewska G, Gabryelewicz A. The effect of a cholecystokinin antagonist lorglumid on the proteinase-antiproteinase balance in taurocholate acute experimental pancreatitis in rats. Mater Med Pol 1992; 24: 223-226.
20. Toriumi Y, Samuel I, Wilcockson DP, Turkelson CM, Solomon TE, Joehl RJ. Octreotide and cholecystokinin antagonist reduce edema in obstruction-induced acute pancreatitis. J Lab Clin Med 1993; 122: 450-454.
21. Aho HJ, Koskensalo SML, Nevalainen TJ. Experimental pancreatitis in the rat. Sodium taurocholate-induced acute haemorrhagic pancreatitis. Scand J Gastroenterol 1980; 15: 411-416.
22. Caraway WT. A stable starch substrate for determination of amylase in serum and other body fluids. Am J Clin Pathol 1969; 32: 97-99.
23. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
24. Bernfeld P. Amylase α and β, in Methods in Enzymology, vol. 1, Colowick SP, Kaplan NO, eds., Academic, New York, 1955; pp. 149-158.
25. Hummel BD. A modified spectrophotometric determination of chymotrypsin, trypsin, and thrombin. Can J Biochem Physiol 1959; 37: 1393-1399.
26. Niederau C, Liddle RA, Ferrell LD, Grendell JH. Beneficial effects of cholecystokinin receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. J Clin Invest 1986; 78: 1056-1063.
27. Czako L, Otsuki M. Pancreatic fluid hypersecretion in acute experimental pancreatitis. Gastroenterology 1995; 108: A349.
28. Saluja AK, Saluja H, Printz A, Zavertnik A, Sengupta A, Steer ML. Experimental pancreatitis is mediated by low-affinity cholecystokinin receptors that inhibit digestive enzyme secretion. Proc Natl Acad Sci USA 1989; 86: 8968-8971.
29. Xia YF. An electron microscopical study on the pathogenesis of taurocholate-induced acute pancreatitis. Chinese J Pathol 1993; 22: 30-32
30. Otsuki M, Tani S, Okabayashi Y, Fuji M, Nakamura T, Fujisawa T, Itoh H. Beneficial effects of the synthetic trypsin inhibitor camostate in cerulein-induced pancreatitis in rats. Dig Dis Sci 1990; 35: 242-250.
31. Suzuki M, Isaji S, Stanten R, Frey CF, Ruebner B. Effect of protease inhibitor FUT-175 on acute hemorrhagic pancreatitis in mice. Int J Pancreatol 1992; 11: 59-65.
32. Büchler M, Malfertheiner P, Uhl W, Martini M, Beger HG. The German multicenter double-blind randomized study of gabexate-mesilate (4 g/day i.v.) in acute pancreatitis. Gastroenterology 1990; 98: A214.
33. Leonhardt U, Seidensticker F, Stöckmann F, Creutzfeldt W. Effect of camostate administration for two weeks on experimental pancreatitis in mice and rats. Pancreas 1993; 8: 98-102.
34. Garcia-Montero AC, Manso MA, Rodiguez I, De Dios I. Therapeutic and protective effect of subcutaneous injections of L-364,718 on cerulein induced pancreatitis. Pancreas 1994; 9: 309-315
35. Agarwal N, Pitchumoni CS. Assessment of severity in acute pancreatitis. Am J Gastroenterol 1991; 86: 1385-1391.